抗结核药物性肝损伤相关危险因素研究进展

doi:10.3969/j.issn.2096-8493.20210055

摘要/Abstract

摘要：

中国仍然是结核病高负担国家,抗结核药物性肝损伤 (anti-tuberculosis drug-induced liver injury,ATLI)是在抗结核治疗过程中常见的不良反应之一,危害性较大。ATLI是影响抗结核治疗成败的关键因素之一,导致ATLI的危险因素有很多。作者从宿主因素、药物因素、环境因素等方面,将近年来ATLI危险因素的研究进展做一综述。

关键词: 抗结核药, 药物性肝损伤, 危险因素

Abstract:

China is still a country with a high burden of tuberculosis. Anti-tuberculosis drugs drug-induced liver injury (ATLI) is one of the common adverse reactions during the anti-tuberculosis treatment and rather harmful. ATLI is one of the key factors that affect the anti-tuberculosis treatment. There are many risk factors for ATLI. The research progress of ATLI risk factors in recent years were reviewed from the host factors, drug factors, environmental factors and so on.

Key words: Antitubercular agents, Drug-induced liver injury, Risk factors

顾宇人, 唐佩军. 抗结核药物性肝损伤相关危险因素研究进展[J]. 结核与肺部疾病杂志, 2021, 2(3): 283-288. doi: 10.3969/j.issn.2096-8493.20210055

GU Yu-ren, TANG Pei-jun. Research progress on risk factors of liver injury caused by anti-tuberculosis drugs[J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 283-288. doi: 10.3969/j.issn.2096-8493.20210055

参考文献 59

[1]	World Health Organization. Global tuberculosis report 2020. Geneva:World Health Organization, 2020.
[2]	中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版). 中华结核和呼吸杂志, 2019, 42(5):343-356. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007
[3]	朱春波, 贺娟, 徐贵丽. 抗结核药肝损伤与药物代谢基因多态性相关研究进展. 西南国防医药, 2017, 27(10):1138-1141. doi: 10.3969/j.issn. 1004-0188.2017.10.041. doi: 10.3969/j.issn. 1004-0188.2017.10.041
[4]	曹鑫宇, 薛秒, 文艳, 等. 抗结核药物性肝损伤易感基因研究进展. 中国防痨杂志, 2021, 43(2):190-193. doi: 10.3969/j.issn.1000-6621.2021.02.016. doi: 10.3969/j.issn.1000-6621.2021.02.016
[5]	Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol, 2013, 3(1):37-49. doi: 10.1016/j.jceh.2012.12.001. doi: 10.1016/j.jceh.2012.12.001 URL
[6]	Wang Y, Xiang X, Wu SQ, et al. Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population. Infect Genet Evol, 2017, 51:198-202. doi: 10.1016/j.meegid.2017.04.001. doi: S1567-1348(17)30114-4 pmid: 28389387
[7]	安慧茹, 吴雪琼, 王仲元. N-乙酰基转移酶2及锰超氧化物歧化酶基因多态性与抗结核药物性肝损害的关系研究. 中国抗生素杂志, 2016, 41(1):70-75. doi: 10.3969/j.issn.1001-8689.2016.01.01. doi: 10.3969/j.issn.1001-8689.2016.01.01
[8]	Yang M, Qiu Y, Jin Y, et al. NR1I2 genetic polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity: A systematic review and meta-analysis. Pharmacol Res Perspect, 2020, 8(6):e00696. doi: 10.1002/prp2.696. doi: 10.1002/prp2.696
[9]	刘瑜, 高瑞, 陈昱, 等. 抗结核药所致肝损害与药物代谢酶等基因多态性的关联性研究. 中国临床药理学与治疗学, 2015, 20(1):91-95.
[10]	Yang S, Hwang SJ, Park JY, et al. Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ Open, 2019, 9(8):e027940. doi: 10.1136/bmjopen-2018-027940. doi: 10.1136/bmjopen-2018-027940 URL
[11]	Eas A, Jcsg A, Mkf B, et al. Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST. Braz J Infect Dis, 2019, 23(6):381-387. doi: 10.1016/j.bjid.2019.09.003. doi: 10.1016/j.bjid.2019.09.003 URL
[12]	An HR, Wu XQ, Wang ZY, et al. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol, 2012, 39(6):535-543. doi: 10.1111/j.1440-1681.2012.05713.x. doi: 10.1111/j.1440-1681.2012.05713.x URL
[13]	Chamorro JG, Castagnino JP, Aidar O, et al. Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics, 2017, 27(10):363-371. doi: 10.1097/FPC.0000000000000300. doi: 10.1097/FPC.0000000000000300 URL
[14]	Wang MG, Zhang YZ, Zhang M, et al. Association of rs1495741 Single Nucleotide Polymorphism with Susceptibility of Anti-tuberculosis Drug-induced Hepatotoxicity. Sichuan Da Xue Xue Bao Yi Xue Ban, 2018.
[15]	Zhang M, Wang S, Wilffert B, et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br J Clin Pharmacol, 2018, 84(12):2747-2760. doi: 10.1111/bcp.13722. doi: 10.1111/bcp.13722 pmid: 30047605
[16]	王玉鹏, 鲍婕. 异烟肼致肝损伤发病机制的研究进展. 药学实践杂志, 2019, 37(4):289-293. doi: 10.3969/j.issn.1006-0111.2019.04.001. doi: 10.3969/j.issn.1006-0111.2019.04.001
[17]	Medina-Sanson A, Núñez-Enríquez JC, Hurtado-Cordova E, et al. Genotype-Environment Interaction Analysis of NQO1, CYP2E1, and NAT2 Polymorphisms and the Risk of Childhood Acute Lymphoblastic Leukemia: A Report From the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia. Front Oncol, 2020, 10:571869. doi: 10.3389/fonc.2020.571869. doi: 10.3389/fonc.2020.571869 URL
[18]	祖丽娅·沙塔尔, 顾佳怡, 马晨晨, 等. GSTM1、GSTT1基因多态性与抗结核药物所致肝损害的相关性分析. 新疆医科大学学报, 2017, 40(6):762-766. doi: 10.3969/j.issn.1009-5551.2017.06.014. doi: 10.3969/j.issn.1009-5551.2017.06.014
[19]	Rana SV, Morya RK, Malik A, et al. Association of NQO1-C609T antioxidant gene polymorphism with drug induced hepatotoxicity in tuberculosis patients. J Clin Exp Hepatol, 2018, 8(1):S82. doi: 10.1016/j.jceh.2018.06.422. doi: 10.1016/j.jceh.2018.06.422
[20]	Ji GY, Wang Y, Wu S Q, et al. Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study. Genet Mol Res, 2016, 15(3). doi: 10.4238/gmr.15038296. doi: 10.4238/gmr.15038296
[21]	Tao B, Yang M, Chen H, et al. Association of ABO blood group and antituberculosis drug-induced liver injury: A case-control study from a Chinese Han population. J Clin Pharm Ther, 2020, 45(4):638-645. doi: 10.1111/jcpt.13139. doi: 10.1111/jcpt.13139 URL
[22]	Liu F, Jiao AX, Wu XR, et al. Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatoto-xicity in Chinese pediatric patients. PLoS One, 2014, 9(12):e115410. doi: 10.1371/journal.pone.0115410. doi: 10.1371/journal.pone.0115410 URL
[23]	Bouazzi OE, Hammi S, Bourkadi JE, et al. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors. Pan Afr Med J, 2016, 25:167. doi: 10.11604/pamj.2016.25.167.10060. doi: 10.11604/pamj.2016.25.167.10060 pmid: 28292129
[24]	葛斐林, 薛春苗, 孙燕, 等. 我国DILI的药物流行病学研究进展. 肝脏, 2018, 23(11):1032-1034. doi: 10.3969/j.issn.1008-1704.2018.11.030. doi: 10.3969/j.issn.1008-1704.2018.11.030
[25]	周媛. 中国人群药物性肝损害的流行病学:系统分析患者21789例. 重庆:第三军医大学, 2013.
[26]	李凌未, 马凌飞, 李胜前. 412例抗结核药物导致肝损害的临床评价分析. 药物流行病学杂志, 2016, 25(12):773-776.
[27]	Bonkovsky HL, Barnhart HX, Foureau DM, et al. Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group. PLoS One, 2018, 13(10):e0206389. doi: 10.1371/journal.pone.0212394. doi: 10.1371/journal.pone.0212394 URL
[28]	杨学敏, 沈宝荣, 刘鹏园, 等. 抗结核药致药物性肝损伤药物性损伤危险因素的logistic回归分析. 中国医院药学杂志, 2019, 39(1):67-71. doi: 10.13286/j.cnki.chinhosppharmacyj.2019.01.15. doi: 10.13286/j.cnki.chinhosppharmacyj.2019.01.15
[29]	Abbasi MA, Ahmed N, Suleman A, et al. Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity. J Ayub Med Coll Abbottabad, 2014, 26(3):384-388.
[30]	Kim WS, Lee SS, Lee CM, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis, 2016, 16:50. doi: 10.1186/s12879-016-1344-2. doi: 10.1186/s12879-016-1344-2 URL
[31]	Chang TE, Huang YS, Chang CH, et al. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis. J Chin Med Assoc, 2018, 81(2):111-118. doi: 10.1016/j.jcma.2017.10.002. doi: 10.1016/j.jcma.2017.10.002 URL
[32]	Chen L, Bao D, Gu L, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis, 2018, 18(1):295. doi: 10.1186/s12879-018-3192-8. doi: 10.1186/s12879-018-3192-8 URL
[33]	Lee SS, Lee CM, Kim TH, et al. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2016, 20(6):800-805. doi: 10.5588/ijtld.15.0668. doi: 10.5588/ijtld.15.0668 pmid: 27155184
[34]	沈弢, 段昭君, 庄辉. 药物性肝损伤的流行病学. 肝脏, 2015, 20(10):819-823. doi: 10.3969/j.issn.1008-1704.2015.10.020. doi: 10.3969/j.issn.1008-1704.2015.10.020
[35]	Naidoo S, Evans D, Jong E, et al. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury. S Afr Med J, 2015, 105(5):393-396. doi: 10.7196/samj.8217. doi: 10.7196/samj.8217 URL
[36]	Rajasingham R, Pollock NR, Linas BP. The Cost-effectiveness of a Point-of-Care Paper Transaminase Test for Monitoring Treatment of HIV/TB Co-Infected Persons. Open Forum Infect Dis, 2017, 4(4):ofx194. doi: 10.1093/ofid/ofx194. doi: 10.1093/ofid/ofx194
[37]	Sharma D, Goel NK, Sharma MK, et al. Prevalence of Diabetes Mellitus and its Predictors among Tuberculosis Patients Currently on Treatment. Indian J Community Med, 2018, 43(4):302-306. doi: 10.4103/ijcm.IJCM_230_18. doi: 10.4103/ijcm.IJCM_230_18
[38]	Hella J, Cercamondi CI, Mhimbira F, et al. Anemia in tuberculosis cases and household controls from Tanzania: Contribution of disease, coinfections, and the role of hepcidin. PLoS One, 2018, 13(4):e0195985. doi: 10.1371/journal.pone.0195985. doi: 10.1371/journal.pone.0195985 URL
[39]	Van Crevel R, Koesoemadinata R, Hill PC, et al. Clinical management of combined tuberculosis and diabetes. Int J Tuberc Lung Dis, 2018, 22(12):1404-1410. doi: 10.5588/ijtld.18.0340. doi: 10.5588/ijtld.18.0340 pmid: 30606312
[40]	Abbara A, Chitty S, Roe JK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis, 2017, 17(1):231. doi: 10.1186/s12879-017-2330-z. doi: 10.1186/s12879-017-2330-z pmid: 28340562
[41]	迟旭, 漆沄, 陈娟, 等. 初次抗结核治疗诱发药物性肝损伤药物性肝损伤临床特点及发病危险因素的logistic回归分析. 陕西医学杂志, 2019, 48(1):67-70. doi: 10.3969/j.issn.1000-7377.2019.01.021. doi: 10.3969/j.issn.1000-7377.2019.01.021
[42]	Simkins J, Abbo LM, Camargo JF, et al. Twelve-week rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates. Transplantation, 2017, 101(6):1468-1472. doi: 10.1097/TP.0000000000001329. doi: 10.1097/TP.0000000000001329 URL
[43]	Khoury T, Rmeileh AA, Yosha L, et al. Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. J Clin Transl Hepatol, 2015, 3(2):99-108. doi: 10.14218/JCTH.2015.00007. doi: 10.14218/JCTH.2015.00007
[44]	Ito K. Liver toxicity due to rifampicin monotherapy in latent tuberculosis infection. Kekkaku, 2016, 91(5):509-513.
[45]	Satyaraddi A, Velpandian T, Sharma SK, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis, 2014, 18(2):188-95, i-iii. doi: 10.5588/ijtld.13.0128. doi: 10.5588/ijtld.13.0128
[46]	Goh ZH, Tee JK, Ho HK. An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage. Int J Mol Sci, 2020, 21(10):3714. doi: 10.3390/ijms21103714. doi: 10.3390/ijms21103714 URL
[47]	Zhao H, Si ZH, Li MH, et al. Pyrazinamide-induced hepatotoxicity and gender differences in rats as revealed by a 1H NMR based metabolomics approach. Toxicol Res (Camb), 2016, 6(1):17-29. doi: 10.1039/c6tx00245e. doi: 10.1039/c6tx00245e
[48]	唐颖婧. 抗结核病药物治疗老年肺结核的不良反应及影响因素分析. 中国社区医师, 2020, 36(23):40-41. doi: 10.3969/j.issn.1007-614x.2020.23.019. doi: 10.3969/j.issn.1007-614x.2020.23.019
[49]	Kakisaka K, Suzuki Y, Abe H, et al. Early identification using the referral system prolonged the time to onset for hepatic encephalopathy after diagnosing severe acute liver injury. Sci Rep, 2020, 10(1):17280. doi: 10.1038/s41598-020-74466-2. doi: 10.1038/s41598-020-74466-2 pmid: 33057105
[50]	曹佳薇, 蔡鑫君, 姚君, 等. 获得性免疫缺陷综合征并发肺结核患者结核分枝杆菌的耐药状况. 中国临床药学杂志, 2018, 27(4):260-263. doi: 10.19577/j.1007-4406.2018.04.010. doi: 10.19577/j.1007-4406.2018.04.010
[51]	World Health Organization. Global tuberculosis report 2016. Geneva:World Health Organization, 2016.
[52]	Araújo-Mariz C, Lopes EP, Acioli-Santos B, et al. Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS. PLoS One, 2016, 11(6):e0157725. doi: 10.1371/journal.pone.0157725. doi: 10.1371/journal.pone.0157725 URL
[53]	Lei Q, Zhao Y, Wang H, et al. Simple and sensitive method for the analysis of 14 antituberculosis drugs using liquid chromatography/tandem mass spectrometry in human plasma. Rapid Commun Mass Spectrom, 2020, 34(8):e8667. doi: 10.1002/rcm.8667. doi: 10.1002/rcm.8667
[54]	Araújo-Mariz C, Lopes EP, Acioli-Santos B, et al. Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS. PLoS One, 2016, 11(6):e0157725. doi: 10.1371/journal.pone.0157725. doi: 10.1371/journal.pone.0157725 URL
[55]	Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109(7):950-66; quiz 967. doi: 10.1038/ajg.2014.131. doi: 10.1038/ajg.2014.131
[56]	何涛, 汪峰, 唐武. 抗结核药致药物性肝损伤ATLI危险因素的logistic回归分析. 中国药房, 2016, 27(12):1626-1628. doi: 10.6039/j.issn.1001-0408.2016.12.15. doi: 10.6039/j.issn.1001-0408.2016.12.15
[57]	王萍, 李秀婷. 酒精对成人肺结核抗结核药物肝损伤的影响. 中国现代药物应用, 2013, 7(15):53-54. doi: 10.3969/j.issn.1673-9523.2013.15.040. doi: 10.3969/j.issn.1673-9523.2013.15.040
[58]	Zaverucha-do-Valle C, Monteiro SP, El-Jaick KB, et al. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients. Tuberculosis (Edinb), 2014, 94(3):299-305. doi: 10.1016/j.tube.2014.03.006. doi: 10.1016/j.tube.2014.03.006 URL
[59]	Li T, Cao Y, Li B, et al. The biological effects of radiation-induced liver damage and its natural protective medicine. Prog Biophys Mol Biol, 2021:S0079-6107(21)00072-9. doi: 10.1016/j.pbiomolbio.2021.06.012. doi: 10.1016/j.pbiomolbio.2021.06.012